In the univariate analysis, the cumulative incidence of overall chronic GVHD significantly differed with the administration and timing of G‐CSF initiation following BMT (p = .012) and CBT (p = .018), but not PBSCT (p = .215) (Figure 3D–F). The gene discussed is CSF3; the disease is chronic graft versus host disease.